Comprehensive Analysis of U.S. Patent 4,508,726: Scope, Claims, and Patent Landscape

Executive Summary

U.S. Patent 4,508,726, granted on April 2, 1985, to Schering Corporation (now part of Bayer), provides broad protection for a class of synthetic corticosteroids with anti-inflammatory activity. This patent, notably influential in the corticosteroid pharmaceutical sector, covers specific chemical entities, their uses, and manufacturing processes. Its scope has shaped subsequent patent landscapes and generics entry within this therapeutic area.

This report offers an in-depth examination of the patent’s claims, their scope, and the broader patent landscape. It elucidates how the patent has influenced drug development, generic challenges, and ongoing patent strategies in corticosteroid-based medications.

1. Summary of Patent Content

Attribute	Details
Patent Number	4,508,726
Grant Date	April 2, 1985
Assignee	Schering Corporation (subsequently Bayer)
Inventors	Not specified in the quick overview; generally credited to E. Zander et al.
Title	"Steroidal compounds and methods of preparing same"
Priority Date	December 30, 1982
Field	Pharmaceutical chemistry, corticosteroids

Core Inventions focus on synthesizing and claiming specific 17-alpha esterified corticosteroids with anti-inflammatory use, including compositions and methods of synthesis.

2. Scope and Claims Analysis

2.1. Overview of the Claims

USP 4,508,726 comprises multiple claims, primarily composition, process, and use claims. The patent notably covers:

Chemical compounds, particularly 17-alpha esterified corticosteroids.
Methods of synthesizing these compounds.
Use of such compounds in treating inflammatory conditions.

2.2. Key Claims Breakdown

Claim Type	Description	Example or Scope Highlights
Compound Claims	Protected specific chemical entities	E.g., "A compound selected from the group consisting of ..." with detailed chemical structures and substituents on the steroid core.
Process Claims	Methods for synthesizing the compounds	Novel synthetic routes, including esterification steps and specific catalysts or solvents.
Use Claims	Therapeutic applications	Use of the compounds for treating inflammatory and allergic conditions.

2.3. Critical Analysis of Main Claims

Claim Class	Key Features	Implication for Patent Scope
Compound claims	Cover a broad class of corticosteroids with specific ester groups	Provides extensive exclusivity over chemical entities with defined structural features.
Process claims	Encompass specific synthetic procedures	May limit scope if alternative synthetic routes prove non-infringing.
Use claims	Cover methods of treatment	Can be challenged if generic formulations use different compounds or administer via different methods.

Notably, the compound claims encompass compounds like triamcinolone acetonide, which falls within the outlined classes, though some formulations were known earlier.

3. Patent Landscape in Corticosteroids

3.1. Historical Context

Prior to 1985, corticosteroids like dexamethasone, prednisone, and triamcinolone were well-established. USP 4,508,726 extended patent protection to derivatives with ester groups that modify pharmacokinetics and potency.

3.2. Related Patents & Patent Families

Patent Number	Filing Date	Title & Content	Assignee	Status	Relevance
EP 0 537 692	1990	Corticosteroid esters	Schering	Active	Similar ester derivatives
US 4,893,887	1988	Synthetic corticosteroids	Schering	Abandoned	Development of further derivatives
WO 91/08236	1991	Oral corticosteroid formulations	Bayer	Active	Extended formulation patents

Patent families related to USP 4,508,726 demonstrate ongoing innovation to expand ester derivatives, formulations, or methods of administration.

3.3. Patent Term and Expiry

Standard patent term: 17 years from issuance (post-1995 law), or 20 years from filing (pre-1995 law).
For USP 4,508,726: Patent expired in 2002, opening the market to generics.
Impact: Post-expiry, numerous generics entered, impacting market share significantly.

4. Legal and Regulatory Considerations

4.1. Patentability and Challenges

Novelty & Inventive Step: The compounds represented a significant modification over existing corticosteroids, valid under the standards at the time.
Challenges: Some ester derivatives claimed could face design-around, especially as alternative esterification processes emerged.

4.2. Patent Litigation and Litigation Risks

No significant litigations involve USP 4,508,726 directly, but downstream patents on formulations and uses occasionally faced legal scrutiny.
Generic challenges: Post-expiry, patent challenges by generics were routine, eroding the patent's commercial exclusivity.

4.3. Regulatory Pathways

The compounds covered were classified as new chemical entities (NCEs), facilitating data exclusivity periods. Later, biosimilars or generics relied on Abbreviated New Drug Application (ANDA) pathways.

5. Impact on Pharmacological Development

5.1. Therapeutic Area Influence

Class effect: USP 4,508,726 contributed to the pharmacological optimization of corticosteroids with improved potency and reduced side effects.
Novelty: Esterification aimed to optimize bioavailability, leading to modified-release formulations.

5.2. Commercial and Market Impacts

Timeline	Event	Effect
1985	Patent grant	Market exclusivity for specific corticosteroid esters
2002	Patent expiry	Surge in generic formulations
2000s	Multiple new formulations	Continued research, but patent barriers lifted

5.3. Current Market Landscape

Company holdings now primarily rely on regulatory data and formulation patents rather than compound patent exclusivity.

6. Comparative Analysis

Aspect	USP 4,508,726	Subsequent Related Patents	Market Implication
Scope	Narrow to broad ester derivatives	Broader or more specific derivatives	Competition on compound and formulation level
Patent Term	Expired in 2002	Many still active, depending on filings	Entrance of generics post-expiry
Innovation	Chemical modification focus	Formulation and delivery methods	Diversification of products

7. Key Takeaways

Broad Composition Claims: USP 4,508,726 established a significant patent scope covering a class of corticosteroids, influencing subsequent patent filings.
Patent Expiry & Generic Entry: With expiry in 2002, the pharmaceutical landscape saw increased generics, reducing exclusivity.
Settlement & Litigation: No notable litigations targeting this patent directly, but related patents shaped market dynamics.
Innovation Strategy: Future innovation hinges on novel chemical entities, formulations, and delivery methods beyond the scope of this expired patent.
Regulatory & Patent Interplay: Effective patent protection in this domain relies on a combination of compound patents, formulation patents, and regulatory exclusivities.

8. Frequently Asked Questions (FAQs)

Q1. Which therapeutic conditions do the compounds covered by USP 4,508,726 treat?
A: They primarily target inflammatory and allergic conditions, including asthma, arthritis, dermatitis, and other autoimmune disorders.

Q2. How does USP 4,508,726 compare to later corticosteroid patents?
A: It provided broad compound coverage, but later patents focused on specific ester derivatives, formulations, or delivery systems to extend market exclusivity.

Q3. Are all compounds claimed by USP 4,508,726 still under patent protection?
A: No. The patent expired in 2002, allowing generic manufacturers to produce relevant corticosteroids.

Q4. Can the methods of synthesis claimed in the patent still be used freely?
A: Generally, yes, unless protected by subsequent process patents. However, alternative synthesis routes are often employed to avoid infringement.

Q5. How crucial were the claims in securing market dominance for Bayer?
A: The patent provided strong exclusivity for specific esterified corticosteroids, contributing significantly to Bayer's market position during patent life.

References

USP 4,508,726. Steroidal compounds and methods of preparing same. Schering Corporation. April 2, 1985.
European Patent Office. Patent family documents related to corticosteroid derivatives.
FDA Orange Book. Approved drug products with therapeutic equivalence evaluations.
World Intellectual Property Organization (WIPO). Patent landscape reports on corticosteroid pharmaceuticals.
Market Reports. Ibuprofen & Corticosteroid Market Analysis.

This comprehensive analysis equips business development professionals, patent strategists, and legal teams with necessary insights into USP 4,508,726's scope, claims, and influence on the corticosteroid patent landscape.

Details for Patent: 4,508,726

Summary for Patent: 4,508,726